AUSTIN, Texas, Aug. 5 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN), a leading developer of biopharmaceutical products for the treatment of cancer and other diseases, will hold its quarterly conference call to discuss second quarter results on Tuesday, August 9, 2005, at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). This call is being webcast by Thomson/CCBN and can be accessed at Introgen's Web site at http://www.introgen.com . The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at http://www.fulldisclosure.com , Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (http://www.streetevents.com ). About Introgen Therapeutics, Inc. Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using non-integrating tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. Contact Information: Channing Burke (512) 708-9310 Ext. 322 email@example.com
SOURCE Introgen Therapeutics, Inc.